Search This Blog

Tuesday, July 28, 2026

GSK launches $2.5B cost-cutting program and beats Q2 estimates

 

GSK launches $2.5B cost-cutting program and beats Q2 estimates with adjusted EPS $1.36, revenue $11.28B

  • New $2.5 billion cost-cutting program aims to accelerate development of GSK's drug pipeline.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)